Home > Company > History

History

  • Launching the new Stem cell media cosmetic line ‘Stem-C’
  • Changed representative system (Kim Seong Rae selected as an representative)
  • Selected as ‘A Promising Export SME' (Small and Medium Business Administration)
  • Clinical study for commercialization of critical lower limb ischemia using stem cell(Cellgram-CLI) (IND-I phase) approved – MFDS(KFDA)
  • Clinical study for commercialization of impotence drug(Cellgram-ED) (IND-I phase) approved – MFDS(KFDA)
  • Small scale merger of IDB- Chem Co., Ltd.
  • Obtained SFDA hygien certificate of China
  • Commenced OEM business of cosmetics containing stem cell culture media
  • Acquisition of IDB- Chem Co., Ltd. (forerunner of Biochemical Business Division)
  • Clinical study for commercialization of alcoholic cirrhosis drug using stem cell(Cellgram-Liver) (IND-III phase) approved – KFDA
  • Changed its name to ‘Pharmicell Co., Ltd.'
  • The world first stem cell drug, ‘Hearticellgram-AMI’ approved - KFDA
  • Won grand prize at Public Health Industry Technology Award in the area of industrial development (Ministry of Health and Welfare)
  • Completed Seongnam GMP factory
  • Commenced stem cell culture media cosmetic products
  • Registered patent : USA patent with dendritic cell production technology for anticancer immune treatment (No.7390658)
  • Selected as ‘The World Best Next Generation Product Corporation' (Ministry of Knowledge and Economy)
  • Clinical study for commercialization of spinal cord injury drug using stem cell (IND-II/III phase) approved - KFDA
  • Registered patent: nerve cell production technology, USA (No. 7229827), Japan(No. 3976190), Australia(No. 2003273118)
  • Clinical study for commercialization of acute myocardial infarction drug, ‘Hearticellgram-AMI’, using stem cell(IND-II/III phase), approved – KFDA
  • Won the grand prize at Public Health Industry Technology Award in the area of research(Ministry of Health and Welfare)
  • Clinical study for commercialization of acute cerebral infarction drug using stem cell (IND-III phase) approved - KFDA
  • Commenced adult stem cell banking business
  • Registered patent: high-functional dendritic cell production technology for anticancer immune treatment using stem cell (No. 0429140)
  • Registered patent: nerve cell production technology for treatment of brain/nervous system disease using stem cell (No. 0449141)
  • Opened cell treatment center in Wonju Severance Christian Hospital
  • Established the company